D. Boral Capital Reiterates Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)

Key Points

• D. Boral Capital has reiterated a "buy" rating for OS Therapies (OSTX), setting a price target of $20.00.
• Shares of OS Therapies opened at $2.04, with a market capitalization of $64.57 million and a significant price-to-earnings ratio of -2.58.
• Recent movements from hedge funds include Bridgeway Capital Management acquiring new shares valued at $47,000 and CM Management increasing its stake by 172.6% to own 300,000 shares.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report)'s stock had its "buy" rating restated by research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $20.00 price target on the stock.

OS Therapies Stock Performance

Shares of OSTX opened at $2.04 on Friday. The company has a market cap of $64.57 million, a price-to-earnings ratio of -2.58 and a beta of -4.09. OS Therapies has a 1-year low of $1.12 and a 1-year high of $7.00. The company's fifty day simple moving average is $2.10 and its 200 day simple moving average is $1.83.

Hedge Funds Weigh In On OS Therapies

Institutional investors and hedge funds have recently modified their holdings of the stock. Bridgeway Capital Management LLC acquired a new position in shares of OS Therapies in the second quarter valued at $47,000. XTX Topco Ltd acquired a new position in shares of OS Therapies in the second quarter valued at about $63,000. Finally, CM Management LLC grew its stake in shares of OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $462,000 after acquiring an additional 189,956 shares in the last quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.